PD-L1 was performed for research/academic interest only; the patient or her insurance was not billed. Invasive carcinoma of the breast not otherwise specified, with HER2 Dual In Situ Hybridization positive for HER2 amplification (HER2 gene average signals 4.0 and Chr17 average signals 2.0, with a ratio of 2.0). This evidence concerns the gene ERBB2 and carcinoma.